Drug Pricing: Page 5


  • Image attribution tooltip
    Win McNamee / Staff via Getty Images
    Image attribution tooltip

    Biden discusses drug prices, mental health services in annual address

    The president also announced a "test-to-treat" program that would allow people to receive free antiviral pills, such as Pfizer's Paxlovid or Merck's molnupiravir, after a COVID-19 test at a pharmacy.

    By Shannon Muchmore • March 2, 2022
  • Federal Trade Commission Chair Lina Khan voted in favor of the study.
    Image attribution tooltip
    Retrieved from FTC.
    Image attribution tooltip

    FTC deadlocks on vote to launch study into PBM practices

    The antitrust agency won't study pharmacy benefit managers' pricing and contract practices as proposed, after a 2-2 vote by commissioners Thursday.

    By Samantha Liss • Feb. 17, 2022
  • Explore the Trendline
    Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip
    Trendline

    Drug pricing

    Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.

    By BioPharma Dive staff
  • Colorized scanning electron micrograph of a cell heavily infected with SARS-CoV-2 virus particles, isolated from a patient sample
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip

    Lilly's new COVID-19 antibody becomes US' latest tool to battle omicron

    The speedy clearance of Lilly’s bebtelovimab comes after the U.S. stopped distributing two of the company's earlier antibodies because they couldn't effectively neutralize the variant.

    By Updated Feb. 11, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA sends signal with tough questions of Lilly at cancer drug meeting

    The agency criticized Eli Lilly for using a trial run in China to seek approval of an immunotherapy it licensed from Innovent Biologics. Outside advisers agreed in a decisive vote that could have repercussions for several other drugmakers.

    By Feb. 10, 2022
  • Lilly slows FDA submission of Alzheimer's drug after Medicare decision

    Executives for the pharma downplayed the impact of an accelerated approval for donanemab, pointing to Medicare's plans to restrict coverage of Alzheimer's drugs like it to only patients in clinical trials.

    By Feb. 3, 2022
  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx
    Image attribution tooltip

    EQRx builds case for cancer drug it hopes can disrupt market

    Study results show EQRx's drug, which it means to position as a lower-cost alternative to widely used cancer immunotherapies, extended the lives of lung cancer patients. But it's unclear whether that will be enough to sway the FDA.

    By Kristin Jensen • Jan. 19, 2022
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Medicare faces blowback over plan to limit coverage of Biogen's Alzheimer's drug

    Biogen, along with allies in industry, plans to pressure Medicare to water down its policy, which limits coverage of Aduhelm and drugs like it to clinical trials.

    By , Jan. 14, 2022
  • After years of decline, drugmakers' price hikes may have bottomed out

    Inflation in 2021 may have offered drugmakers a catalyst for taking slightly bigger increases on a list price basis. But rebates to insurers are still keeping net price rises lower.

    By Jan. 5, 2022
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip
    New Alzheimer's drugs

    After intense pushback, Biogen to cut price of Alzheimer's drug

    Effective Jan. 1, the average list price for Aduhelm will drop about 50% to just over $28,000 a year. It's a move the company hopes will appease insurers and lower out-of-pocket costs for patients.

    By Dec. 20, 2021
  • Image attribution tooltip
    Mark Wilson via Getty Images
    Image attribution tooltip

    Martin Shkreli's former company to pay $40M in settlement over drug price hikes

    The payment resolves the government's claims against Vyera and Phoenixus for their efforts to block competition to Daraprim, the toxoplasmosis drug Shkreli famously raised the price of by 4,000%.

    By Kristin Jensen • Dec. 8, 2021
  • Pharmaceutical Executives Testify At Senate Finance Committee Hearing On Drug Prices
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    As Congress weighs drug price restraints, ICER calls out 'unsupported' increases

    In a new report, ICER highlighted AbbVie's price hikes on Humira, which the group said resulted in more than $1 billion in U.S. spending last year without any new evidence of health benefits.

    By Nov. 16, 2021
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Pfizer will allow generic drugmakers to produce promising COVID-19 pill

    A licensing deal with a U.N.-backed patent group could expand supply of Pfizer's experimental drug Paxlovid in lower- and middle-income countries.

    By Nov. 16, 2021
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Anticipating Aduhelm's costs, Medicare plans big jump in premiums

    While CMS is still weighing whether to authorize wide coverage of Biogen's pricey Alzheimer's drug, administrators are planning to build reserves in case costs skyrocket.

    By Nov. 15, 2021
  • The United States Capitol in February 2020
    Image attribution tooltip
    Megan Quinn/BioPharma Dive
    Image attribution tooltip

    Democrats’ drug pricing plan, while scaled back, could still squeeze pharma top-sellers

    Legislation backed by President Joe Biden and top Democratic lawmakers would allow for price negotiation on 20 older drugs, potentially impacting blockbusters from Pfizer, Bristol Myers Squibb and others.

    By Nov. 4, 2021
  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    A three-decade monopoly: how Amgen built a patent thicket around its top-selling drug

    Through high-stakes litigation, aggressive patenting practices and a bit of luck, Amgen will likely stretch Enbrel's monopoly until 2029, more than 30 years after it was approved.

    By Nov. 1, 2021
  • Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    Drug price restraints dropped as Biden prioritizes other measures

    Despite majority control of Congress, it appears unlikely the Biden administration will be able to pass meaningful pricing reform, though a slimmed-down bill may still be in the works.

    By Oct. 29, 2021
  • Image attribution tooltip
    Jon Cherry via Getty Images
    Image attribution tooltip

    J&J foresees end to not-for-profit sales of coronavirus vaccine

    The drugmaker plans to switch over to a commercial business model late next year or early in 2023, said Jennifer Taubert, head of J&J's pharma division.

    By Oct. 19, 2021
  • Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat

    The interchangeable approval could help to boost adoption of Boehringer's biosimilar when it launches in mid-2023, a date set via settlement with AbbVie.

    By Oct. 18, 2021
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Insurers sue Merck for 'monopolistic scheme' to delay generics of blockbuster cholesterol drug

    The suits allege an agreement between Merck and a generic manufacturer kept low-cost versions of the drugmaker's widely used Zetia off the market for years.

    By Samantha Liss • Sept. 24, 2021
  • The front of the department of health and human services building with a sign in front of the exterior building
    Image attribution tooltip
    Mark Wilson via Getty Images
    Image attribution tooltip

    Lilly, Novartis, other pharmas could face fines for violating 340B law

    The U.S. health department asked its inspector general to review the refusals of six drugmakers to offer discounts to safety net hospitals through community pharmacy partnerships.

    By Rebecca Pifer • Sept. 24, 2021
  • Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    Biden pushes forward on Medicare price negotiation

    But opposition from the drug industry and congressional Republicans could make the Democrats' signature proposal an uphill battle. 

    By Sept. 10, 2021
  • Coherus, known for biosimilars, nears an immunotherapy battle with big pharma

    New lung cancer results could make Coherus the next entrant in an ultra-competitive market dominated by pricey drugs like Merck's Keytruda.

    By Aug. 19, 2021
  • Image attribution tooltip
    Alex Wong via Getty Images
    Image attribution tooltip

    Biden embraces Medicare drug price negotiation as Democrats seek to widen health coverage

    In a speech Thursday afternoon outlining his proposal, which features several familiar policy ideas, Biden emphasized price negotiation, but allowing for drugmaker profit. 

    By Updated Aug. 12, 2021
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    VA leaves Aduhelm off coverage list, recommending against controversial Alzheimer's drug

    The decision, which does provide for certain exceptions, is another bump in what's become a rocky market rollout for Biogen's medicine. 

    By Updated Aug. 12, 2021
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Startup EQRx to take drug price mission public through $1.8B SPAC deal

    A merger with a blank-check company backed by Casdin Capital will greatly expand the resources available to EQRx, which aims to develop competitors to existing drugs and sell them at "radically lower" prices.

    By Aug. 6, 2021